AEGiS-11IAC: HIV immunity induced by canarypox (ALVAC)-MN gp160,-SF2 rgp120 or both.

11th International AIDS Conference

Vancouver, British Columbia — July 7-12, 1996

HIV immunity induced by canarypox (ALVAC)-MN gp160,-SF2 rgp120 or both.

Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. Mo.A.281)
Clements ML, Weinhold K, Siliciano R, Schwartz D, Matthews T, Graham B, Keefer M, McElrath J, Gorse G, Hsieh R, Duliege A, Excler J, Meigner B, Tartaglia J, Paoletti E; Center for Immunization Research, Baltimore, MD, USA. Fax: 410-550-6898.

OBJECTIVE: To evaluate the priming and boosting effect of two recombinant HIV vaccines.

METHODS: 106 and 107 TCID50 of recombinant canarypox (ALVAC)-HIVMN gp160 and 50 micrograms HIV-1SF2 rgp120 in MF59, were given i.m. to uninfected, vaccinia-naive and vaccinia-immune adults at 0, 1 or 2, 6 or 9, and 12 months. ALVAC-rabies glycoprotein (ARG) served as a control. Vaccines (number of doses) included: ALVAC-gp160 (4), ALVAC-gp160 (2) + rgp120 (2), ARG (2) + rgp120 (2), ARG (4) or rgp120 (4).

RESULTS: Neutralization antibodies, CTL activity, ADCC or lymphoproliferative responses were elicited by each vaccine regimen, as shown below. NT = not tested. (table: see text)

CONCLUSIONS: These results suggest priming with ALVAC-gp160 (particularly the higher dose) and boosting with rgp120 elicited neutralizing antibodies, ADCC, and CTL more often than ALVAC-gp160 or rgp120 alone, regardless of prior vaccinia immune status. These results warrant studies of other ALVAC-HIV recombinants and rgp120.

Keywords: AEGIS, HIV, HIV Envelope Protein gp120, HIV Antibodies, Vaccines, Synthetic, HIV-1, Virus Diseases, HIV Infections, Antibody-Dependent Cell Cytotoxicity, Acquired Immunodeficiency Syndrome, HIV Protease, Adult, immunology, ICA11

960707
MoA281